Key result
Liraglutide was evaluated for its effects on cardiovascular events in patients with type 2 diabetes mellitus stratified by coronary, cerebrovascular, and peripheral vascular territories.
Why the study?
Does liraglutide reduce cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease?
Population
Patients with Type 2 Diabetes Mellitus and Polyvascular Disease
Design
Cohort
Authors
Loading...
Liraglutide effects in polyvascular T2DM remain uncertain; leaves open differential benefits by vascular territory.
Does liraglutide reduce cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease?
Verma et al. (2018) studied this question. Liraglutide was evaluated for its effects on cardiovascular events in patients with type 2 diabetes mellitus stratified by coronary, cerebrovascular, and peripheral vascular territories.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: